4D Molecular Therapeutics (FDMT) Company Cash Balance

4dmoleculartherapeutics.com - graphic logo of issuer FDMT

4D Molecular Therapeutics develops gene therapies for ophthalmology and cardiology, leveraging support from major pharmaceutical partners. Cash balance dynamics demonstrate current liquidity, with the latest value recorded as 0.31. Success depends on the validation of vector technologies and the efficiency of in-house manufacturing. Meanwhile, strict FDA oversight and the closed nature of the clinical trial environment determine access to future patients.

FDMT (4D Molecular Therapeutics Inc) Company Cash Funds history from 07/04/2022 to 11/21/2026

Analytical breakdowns for 4dmoleculartherapeutics.com (FDMT)

- price and consensus price forecast:
Comprehensive company analysis:4dmoleculartherapeutics.com (FDMT)
Brand item of 4D Molecular Therapeutics

Investors are evaluating 4D Molecular Therapeutics (FDMT) through the lens of development costs for innovative AAV vectors used in rare disease therapies. This metric aggregates cash and cash equivalents, determining the company's ability to fund R&D without emergency capital raises. By analyzing cash asset dynamics, one can track the cash burn rate associated with clinical trials. A stable balance confirms financial autonomy and minimizes the risk of default prior to product commercialization.

Competitors of 4D Molecular Therapeutics

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume